376 related articles for article (PubMed ID: 32999024)
101. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
Kong L; Torrents de la Peña A; Deller MC; Garces F; Sliepen K; Hua Y; Stanfield RL; Sanders RW; Wilson IA
Acta Crystallogr D Biol Crystallogr; 2015 Oct; 71(Pt 10):2099-108. PubMed ID: 26457433
[TBL] [Abstract][Full Text] [Related]
102. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.
Lee JH; Nakao C; Appel M; Le A; Landais E; Kalyuzhniy O; Hu X; Liguori A; Mullen TM; Groschel B; Abbott RK; Sok D; Schief WR; Crotty S
Cell Rep; 2022 Mar; 38(10):110485. PubMed ID: 35263576
[TBL] [Abstract][Full Text] [Related]
103. Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model.
Moyo-Gwete T; Ayres F; Mzindle NB; Makhado Z; Manamela NP; Richardson SI; Kitchin D; van Graan S; van Heerden J; Parbhoo N; Chege GK; Moore PL
Sci Rep; 2024 Jun; 14(1):13311. PubMed ID: 38858452
[TBL] [Abstract][Full Text] [Related]
104. Native-like Env trimers as a platform for HIV-1 vaccine design.
Sanders RW; Moore JP
Immunol Rev; 2017 Jan; 275(1):161-182. PubMed ID: 28133806
[TBL] [Abstract][Full Text] [Related]
105. Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.
Georgiev IS; Joyce MG; Yang Y; Sastry M; Zhang B; Baxa U; Chen RE; Druz A; Lees CR; Narpala S; Schön A; Van Galen J; Chuang GY; Gorman J; Harned A; Pancera M; Stewart-Jones GB; Cheng C; Freire E; McDermott AB; Mascola JR; Kwong PD
J Virol; 2015 May; 89(10):5318-29. PubMed ID: 25740988
[TBL] [Abstract][Full Text] [Related]
106. A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
Joshi VR; Claiborne DT; Pack ML; Power KA; Newman RM; Batorsky R; Bean DJ; Goroff MS; Lingwood D; Seaman MS; Rosenberg E; Allen TM
J Virol; 2024 Mar; 98(3):e0172023. PubMed ID: 38412036
[TBL] [Abstract][Full Text] [Related]
107. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
108. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.
Escolano A; Gristick HB; Gautam R; DeLaitsch AT; Abernathy ME; Yang Z; Wang H; Hoffmann MAG; Nishimura Y; Wang Z; Koranda N; Kakutani LM; Gao H; Gnanapragasam PNP; Raina H; Gazumyan A; Cipolla M; Oliveira TY; Ramos V; Irvine DJ; Silva M; West AP; Keeffe JR; Barnes CO; Seaman MS; Nussenzweig MC; Martin MA; Bjorkman PJ
Sci Transl Med; 2021 Nov; 13(621):eabk1533. PubMed ID: 34818054
[TBL] [Abstract][Full Text] [Related]
109. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
Wiehe K; Saunders KO; Stalls V; Cain DW; Venkatayogi S; Martin Beem JS; Berry M; Evangelous T; Henderson R; Hora B; Xia SM; Jiang C; Newman A; Bowman C; Lu X; Bryan ME; Bal J; Sanzone A; Chen H; Eaton A; Tomai MA; Fox CB; Tam YK; Barbosa C; Bonsignori M; Muramatsu H; Alam SM; Montefiori DC; Williams WB; Pardi N; Tian M; Weissman D; Alt FW; Acharya P; Haynes BF
Cell Host Microbe; 2024 May; 32(5):693-709.e7. PubMed ID: 38670093
[TBL] [Abstract][Full Text] [Related]
110. A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.
Gulla K; Cibelli N; Cooper JW; Fuller HC; Schneiderman Z; Witter S; Zhang Y; Changela A; Geng H; Hatcher C; Narpala S; Tsybovsky Y; Zhang B; Vrc Production Program ; McDermott AB; Kwong PD; Gowetski DB
Vaccine; 2021 Jun; 39(25):3379-3387. PubMed ID: 34020817
[TBL] [Abstract][Full Text] [Related]
111. Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
Kuriakose Gift S; Wieczorek L; Sanders-Buell E; Zemil M; Molnar S; Donofrio G; Townsley S; Chenine AL; Bose M; Trinh HV; Barrows BM; Sriplienchan S; Kitsiripornchai S; Nitayapan S; Eller LA; Rao M; Ferrari G; Michael NL; Ake JA; Krebs SJ; Robb ML; Tovanabutra S; Polonis VR
J Virol; 2023 Feb; 97(2):e0163522. PubMed ID: 36749076
[TBL] [Abstract][Full Text] [Related]
112. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.
Derdeyn CA; Moore PL; Morris L
Curr Opin HIV AIDS; 2014 May; 9(3):210-6. PubMed ID: 24662931
[TBL] [Abstract][Full Text] [Related]
113. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.
Crooks ET; Osawa K; Tong T; Grimley SL; Dai YD; Whalen RG; Kulp DW; Menis S; Schief WR; Binley JM
Virology; 2017 May; 505():193-209. PubMed ID: 28279830
[TBL] [Abstract][Full Text] [Related]
114. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
Moore PL; Williamson C; Morris L
Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
[TBL] [Abstract][Full Text] [Related]
115. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
Walker LM; Simek MD; Priddy F; Gach JS; Wagner D; Zwick MB; Phogat SK; Poignard P; Burton DR
PLoS Pathog; 2010 Aug; 6(8):e1001028. PubMed ID: 20700449
[TBL] [Abstract][Full Text] [Related]
116. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.
Hahn WO; Parks KR; Shen M; Ozorowski G; Janes H; Ballweber-Fleming L; Woodward Davis AS; Duplessis C; Tomai M; Dey AK; Sagawa ZK; De Rosa SC; Seese A; Siddaramaiah LK; Stamatatos L; Lee WH; Sewall LM; Karlinsey D; Turner HL; Rubin V; Furth S; MacPhee K; Duff M; Corey L; Keefer MC; Edupuganti S; Frank I; Maenza J; Baden LR; Hyrien O; Sanders RW; Moore JP; Ward AB; Tomaras GD; Montefiori DC; Rouphael N; McElrath MJ
medRxiv; 2024 May; ():. PubMed ID: 38766048
[TBL] [Abstract][Full Text] [Related]
117. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir.
Yu WH; Su D; Torabi J; Fennessey CM; Shiakolas A; Lynch R; Chun TW; Doria-Rose N; Alter G; Seaman MS; Keele BF; Lauffenburger DA; Julg B
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484826
[TBL] [Abstract][Full Text] [Related]
118. Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
Vukovich MJ; Raju N; Kgagudi P; Manamela NP; Abu-Shmais AA; Gripenstraw KR; Wasdin PT; Shen X; Dwyer B; Akoad J; Lynch RM; Montefiori DC; Richardson SI; Moore PL; Georgiev IS
J Virol; 2024 Jan; 98(1):e0147823. PubMed ID: 38085509
[TBL] [Abstract][Full Text] [Related]
119. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.
van Schooten J; Schorcht A; Farokhi E; Umotoy JC; Gao H; van den Kerkhof TLGM; Dorning J; Rijkhold Meesters TG; van der Woude P; Burger JA; Bijl T; Ghalaiyini R; Torrents de la Peña A; Turner HL; Labranche CC; Stanfield RL; Sok D; Schuitemaker H; Montefiori DC; Burton DR; Ozorowski G; Seaman MS; Wilson IA; Sanders RW; Ward AB; van Gils MJ
PLoS Pathog; 2022 Nov; 18(11):e1010945. PubMed ID: 36395347
[TBL] [Abstract][Full Text] [Related]
120. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates.
He W; Ou T; Skamangas N; Bailey CC; Bronkema N; Guo Y; Yin Y; Kobzarenko V; Zhang X; Pan A; Liu X; Xu J; Zhang L; Allwardt AE; Mitra D; Quinlan B; Sanders RW; Choe H; Farzan M
Immunity; 2023 Oct; 56(10):2408-2424.e6. PubMed ID: 37531955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
